Trial · NCT00745875

ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study

NCT00745875, Phase 2, Completed, AstraZeneca; results first posted 2012-06-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study. Trials, record NCT00745875. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00745875

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
NCT number: NCT00745875
Status: Completed
Phases: Phase 2
Enrollment: 66 participants, actual
Lead sponsor: AstraZeneca
Conditions: Non Small Cell Lung Cancer, Lung Cancer
Interventions: ZD4054, Pemetrexed, Placebo
First posted: 2008-09-03
Last updated: 2012-06-06
Results first posted: 2012-06-06

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Time to Death	Patients were followed up for survival every week for the first 3 weeks then every 3 weeks whilst on study medication until the data cut-off (17th January 2010).	Median time (in days) from randomisation until death using the Kaplan-Meier method (Calculator for survival probability)
Secondary	Progression-free Survival	Tumour assessments for progression were performed at screening, every 3 weeks, Mandatory Tumour Assessment Visit (19 August 2009 ± 3 days), treatment discontinuation	Median time (in days) from randomisation until disease progression/death using the Kaplan-Meier method

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Time to Death	Patients were followed up for survival every week for the first 3 weeks then every 3 weeks whilst on study medication until the data cut-off (17th January 2010).		Days	MEDIAN
SECONDARY	Progression-free Survival	Tumour assessments for progression were performed at screening, every 3 weeks, Mandatory Tumour Assessment Visit (19 August 2009 ± 3 days), treatment discontinuation		Days	MEDIAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Time to Death	Placebo + Pemetrexed	193	Full Range 27 to 437	Days
Time to Death	ZD4054 + Pemetrexed	146	Full Range 19 to 427	Days
Progression-free Survival	Placebo + Pemetrexed	87	Full Range 27 to 283	Days
Progression-free Survival	ZD4054 + Pemetrexed	110	Full Range 18 to 303	Days

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo + Pemetrexed	36
Overall Study	STARTED	ZD4054 + Pemetrexed	30
Overall Study	COMPLETED	Placebo + Pemetrexed	32
Overall Study	COMPLETED	ZD4054 + Pemetrexed	26
Overall Study	NOT COMPLETED	Placebo + Pemetrexed	4
Overall Study	NOT COMPLETED	ZD4054 + Pemetrexed	4

Source ClinicalTrials.gov

Adverse events76

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anaemia	Blood and lymphatic system disorders	Placebo + Pemetrexed	8	30
other	Anaemia	Blood and lymphatic system disorders	ZD4054 + Pemetrexed	7	36
other	Neutropenia	Blood and lymphatic system disorders	Placebo + Pemetrexed	5	30
other	Neutropenia	Blood and lymphatic system disorders	ZD4054 + Pemetrexed	1	36
other	Leukopenia	Blood and lymphatic system disorders	Placebo + Pemetrexed	2	30
other	Leukopenia	Blood and lymphatic system disorders	ZD4054 + Pemetrexed	0	36
other	Nausea	Gastrointestinal disorders	Placebo + Pemetrexed	2	30
other	Nausea	Gastrointestinal disorders	ZD4054 + Pemetrexed	5	36
other	Constipation	Gastrointestinal disorders	Placebo + Pemetrexed	2	30
other	Constipation	Gastrointestinal disorders	ZD4054 + Pemetrexed	1	36

1 to 10 of 76Source ClinicalTrials.gov

See all 76 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo + Pemetrexed
Total, all-cause mortality	ZD4054 + Pemetrexed
Total, other adverse events	Placebo + Pemetrexed	22	30
Total, other adverse events	ZD4054 + Pemetrexed	20	36
Total, serious adverse events	Placebo + Pemetrexed	7	30
Total, serious adverse events	ZD4054 + Pemetrexed	4	36

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Placebo + Pemetrexed vs ZD4054 + Pemetrexed: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00745875

GET https://conductscience.org/api/trials/v1/NCT00745875/events?page=2

API reference For AI assistants